er-086526 and Asthenia

er-086526 has been researched along with Asthenia* in 1 studies

Other Studies

1 other study(ies) available for er-086526 and Asthenia

ArticleYear
[Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
    Bulletin du cancer, 2015, Volume: 102, Issue:9

    Eribulin gained its approval in March 2011 for the treatment of patients with locally advanced or metastatic breast cancer (MBC) whose disease has progressed despite anthracycline and taxane-containing regimens. This study retrospectively assessed the efficacy, safety and cost of this treatment for all patients with MBC treated by eribulin in Franche-Comté. Ninety-four patients received eribulin between July 2006 and October 2013. The median age was 62 years (35-83). Median overall survival was 10.3 months [95% CI: 7.6 to 17.9]. Median progression-free-survival was 3.8 months [95% CI: 2.9 to 5.0]. Clinical benefit was obtained in 55% evaluable patients [95% CI: 43.1 to 66.9] by RECIST criteria. Most common grade 3-4 adverse events (AEs) were neutropenia (38%), asthenia (10%) and peripheral neuropathy (7%). Median cost of the treatment was 9767 € per patient (6344-17,517). This analysis found similar results to the EMBRACE study despite less selected population. A medico-economic evaluation cost-utility type would assess the effectiveness of this strategy compared to standard treatments.

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Breast Neoplasms; Female; Furans; Humans; Ketones; Middle Aged; Neutropenia; Peripheral Nervous System Diseases; Retrospective Studies

2015